

RED Project: High Throughput Toxicokinetics (HTTK) and Systematic Empirical Evaluation of Exposure (SEEM)

January 23, 2018




High-Throughput Risk Prioritization

The National Research Council (1983) identified chemical risk as a function of both inherent hazard and exposure

In order to address thousands of chemicals, we need to use “high throughput methods” to prioritize those chemicals most worthy of additional study

High throughput risk prioritization needs:


1. high throughput **hazard** characterization
2. high throughput **exposure** forecasts
3. high throughput **toxicokinetics** (*i.e.*, dosimetry)



High-Throughput Risk Prioritization


Tox21: Examining >8,000 chemicals using ~50 assays intended to identify interactions with biological pathways (Schmidt, 2009)

ToxCast: For a subset (>2000) of Tox21 chemicals ran >1100 additional assay endpoints (Kavlock *et al.*, 2012)



High throughput screening (HTS) for *in vitro* bioactivity allows characterization of thousands of chemicals for which no other testing has occurred

High Throughput Toxicokinetics (HTTK)




In Vitro - *In Vivo* Extrapolation (IVIVE)

Definition:


IVIVE is the utilization of *in vitro* experimental data to predict phenomena *in vivo*

- IVIVE-PK/TK (Pharmacokinetics/Toxicokinetics):
 - Fate of molecules/chemicals in body
 - Considers absorption, distribution, metabolism, excretion (ADME)
 - Uses empirical PK and physiologically-based (PBPK) modeling
- IVIVE-PD/TD (Pharmacodynamics/Toxicodynamics):
 - Effect of molecules/chemicals at biological target *in vivo*
 - Assay design/selection important
 - Perturbation as adverse/therapeutic effect, reversible/irreversible
- Both contribute to predict *in vivo* effects



High-Throughput Toxicokinetics (HTTK)

- **Most chemicals do not have TK data** – we use *in vitro* HTTK methods adapted from pharma to fill gaps
- In drug development, HTTK methods estimate therapeutic doses for clinical studies – predicted concentrations are typically on the order of values measured in clinical trials (Wang, 2010)



A Basic Model Allows HTTK

- *In vitro* plasma protein binding (fraction unbound in plasma – f_{up}) and intrinsic hepatic metabolic clearance (Cl_{int}) assays allow approximate hepatic and renal clearances to be calculated
- At steady state this allows conversion from concentration to administered dose
- 100% bioavailability assumed



$$C_{ss} = \frac{\text{oral dose rate}}{\left(\text{GFR} * F_{up} \right) + \left(Q_l * F_{up} * \frac{Cl_{int}}{Q_l + F_{up} * Cl_{int}} \right)}$$

GFR: Glomerular filtration rate (kidney)


Q_l : Liver blood flow

Minimal Model: Lumped Single Distribution Volume

simCYP
© 2001-2009 Simcyp Limited





Risk-Based Ranking for Total NHANES Population




Ring *et al.* (2017)

Life-stage and Demographic Specific Predictions

- Can calculate margin between bioactivity and exposure for specific populations



Change in Risk Relative to Total Population



All Models and Data Open Source and Public

Download R:

<https://www.r-project.org/>


within R, type:

```
install.packages("httk")
```

Then

```
library("httk")
```

- “httk” R Package for IVIVE and PBTK
- 553 chemicals to date
- 100’s of additional chemicals being studied
- Pearce *et al.* (2017a) provides documentation and examples
- Built-in vignettes provide further examples of how to use many functions



The screenshot shows the CRAN package page for 'httk'. The browser address bar displays <https://cran.r-project.org/web/packages/httk/index.html>. The page title is 'httk: High-Throughput Toxicokinetics'. The description states: 'Functions and data tables for simulation and statistical analysis of chemical toxicokinetics ("TK") using data obtained from relatively high throughput, in vitro studies. Both physiologically-based ("PBTK") and empirical (e.g., one compartment) "TK" models can be parameterized for several hundred chemicals and multiple species. These models are solved efficiently, often using compiled (C-based) code. A Monte Carlo sampler is included for simulating biological variability and measurement limitations. Functions are also provided for exporting "PBTK" models to "SBML" and "JARNAC" for use with other simulation software. These functions and data provide a set of tools for in vitro-in vivo extrapolation ("IVIVE") of high throughput screening data (e.g., ToxCast) to real-world exposures via reverse dosimetry (also known as "RTK").'

Metadata includes:

- Version: 1.7
- Depends: R (≥ 2.10)
- Imports: [deSolve](#), [msm](#), [data.table](#), [survey](#), [mvtnorm](#), [truncnorm](#), stats, utils
- Suggests: [ggplot2](#), [knitr](#), [rmarkdown](#), [R.rsp](#), [GGally](#), [gplots](#), [scales](#), [EnvStats](#), [MASS](#), [RColorBrewer](#), [TeachingDemos](#), [classInt](#), [ks](#), [reshape2](#), [gdata](#), [viridis](#), [CensRegMod](#), [gmodels](#), [colorspace](#)
- Published: 2017-07-15
- Author: John Wambaugh, Robert Pearce, Caroline Ring, Jimena Davis, Nisha Sipes, and R. Woodrow Setzer
- Maintainer: John Wambaugh <wambaugh.john@epa.gov>
- License: [GPL-3](#)
- NeedsCompilation: yes
- Citation: [httk citation info](#)
- Materials: [NEWS](#)
- CRAN checks: [httk results](#)

Downloads: (list of download links)


Reference manual: [httk.pdf](#)

Vignettes: [Creating Partition Coefficient Evaluation Plots](#), [Age distributions](#), [Global sensitivity analysis](#), [Global sensitivity analysis plotting](#), [Height and weight spline fits and residuals](#), [Hematocrit spline fits and residuals](#), [Plotting C_{ss95}](#), [Serum creatinine spline fits and residuals](#), [Generating subpopulations](#), [Evaluating HTTK models for subpopulations](#), [Generating Figure 2](#), [Generating Figure 3](#), [Plotting Howgate/Johnson data](#)

A blue box highlights the URL: <https://CRAN.R-project.org/package=httk>

New Exposure Data and Models



High throughput screening + *in vitro-in vivo* extrapolation (IVIVE can predict a dose (mg/kg bw/day) that might be adverse



High throughput models exist to make predictions of exposure via specific, important pathways such as residential product use, diet, and environmental fate

Consensus Exposure Predictions with the SEEM Framework

- We incorporate multiple models (including SHEDS-HT, ExpoDat) into consensus predictions for 1000s of chemicals within the **Systematic Empirical Evaluation of Models (SEEM)** framework
- We evaluate/calibrate predictions with available monitoring data
- This provides information similar to a sensitivity analysis: What models are working? What data are most needed? This is an iterative process



Integrating Multiple Models

Exposures Inferred from NHANES

- Annual survey, data released on 2-year cycle.
- Different predictive models provide different chemical-specific predictions
 - Some models may do a better job form some chemical classes than others overall, so we want to evaluate performance against monitoring data
- Separate evaluations can be done for various demographics

National Health and Nutrition Examination Survey

Urinary Bisphenol A (2,2-bis[4-Hydroxyphenyl] propane)

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population and Nutrition Examination Survey.

	Survey years	Geometric mean	Selected percentiles		
		(95% conf. interval)	(95% confidence interval)		
			50th	75th	90th
Total	03-04	2.64 (2.38-2.94)	2.80 (2.50-3.10)	5.50 (5.00-6.20)	10.6 (9.40-12.0)
	05-06	1.90 (1.79-2.02)	2.00 (1.90-2.00)	3.70 (3.50-3.90)	7.00 (6.40-7.60)
	07-08	2.08 (1.92-2.26)	2.10 (1.90-2.30)	4.10 (3.60-4.60)	7.70 (6.80-8.60)
Age group 6-11 years	03-04	3.55 (2.95-4.29)	3.80 (2.70-5.00)	6.90 (6.00-8.30)	12.6 (9.50-15.7)
	05-06	2.86 (2.52-3.24)	2.70 (2.30-2.90)	5.00 (4.40-5.80)	13.5 (9.30-18.7)
	07-08	2.46 (2.20-2.75)	2.40 (1.90-3.00)	4.50 (3.70-5.50)	7.00 (6.30-7.70)
12-19 years	03-04	3.74 (3.31-4.22)	4.30 (3.60-4.60)	7.80 (6.50-9.00)	13.5 (11.8-15.2)
	05-06	2.42 (2.18-2.68)	2.40 (2.10-2.70)	4.30 (3.90-5.20)	8.40 (6.50-10.3)
	07-08	2.44 (2.14-2.78)	2.30 (2.10-2.60)	4.40 (3.70-5.50)	9.70 (7.30-12.1)
20 years and older	03-04	2.41 (2.15-2.72)	2.60 (2.30-2.80)	5.10 (4.50-5.70)	9.50 (8.10-10.9)
	05-06	1.75 (1.62-1.89)	1.80 (1.70-2.00)	3.40 (3.10-3.70)	6.40 (5.80-7.00)
	07-08	1.99 (1.82-2.18)	2.00 (1.80-2.30)	3.90 (3.40-4.60)	7.40 (6.60-8.20)

CDC, Fourth National Exposure Report (2011)

Chemical Use Identifies Relevant Pathways

- **The exposure event is unobservable**
 - But we can try to predict exposure by characterizing pathway
- Some pathways have much higher average exposures!
 - In home “Near field” sources significant (Wallace, *et al.*, 1987)
- Chemical-Product Database (<https://actor.epa.gov/cpcat/>) provides chemical use information (Dionisio et al., 2015)






Figure from Kristin Isaacs

Human Exposure Predictions for 134,521 Chemicals



- Machine learning models were built for each four exposure pathways
- Pathway predictions can be used for large chemical libraries
- Use prediction (and accuracy of prediction) as a prior for Bayesian analysis
- Each chemical may have exposure by multiple pathways

Human Exposure Predictions for 134,521 Chemicals



95% confident that median population would
be <LOD for thousands of chemicals

Ring et al. (*in prep.*)

Ecological SEEM

